Loading...
Market
Adoption rate of Imfinzi in top cancer treatment centers
1
Resolution / Starting Odds
Less than 25% • 33%
25%-50% • 33%
More than 50% • 33%
Reports from top cancer treatment centers and healthcare analytics firms
Story
FDA Approves Imfinzi Combo for dMMR Advanced Endometrial Cancer
Jun 17, 2024, 08:12 AM
The U.S. Food and Drug Administration (FDA) has approved the use of durvalumab in combination with carboplatin and paclitaxel, followed by single-agent durvalumab, for adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR). This approval, announced on June 14, is based on the Duo-E subgroup analysis. Durvalumab, marketed as IMFINZI®, is produced by AstraZeneca (AZN).
View original story
Similar markets
Less than 10% • 25%
10%-20% • 25%
20%-30% • 25%
More than 30% • 25%
North America • 25%
Europe • 25%
Asia-Pacific • 25%
Other • 25%
Yes • 50%
No • 50%
Optune Lua with PD-1/PD-L1 inhibitors • 25%
Sunvozertinib • 25%
Durvalumab with chemotherapy • 25%
Other • 25%
Yes • 50%
No • 50%
North America • 25%
Europe • 25%
Asia-Pacific • 25%
Other regions • 25%
Lung cancer • 25%
Breast cancer • 25%
Colorectal cancer • 25%
Other • 25%